184 related articles for article (PubMed ID: 15791436)
1. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.
Seidl C; Schröck H; Seidenschwang S; Beck R; Schmid E; Abend M; Becker KF; Apostolidis C; Nikula TK; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):274-85. PubMed ID: 15791436
[TBL] [Abstract][Full Text] [Related]
2. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.
Beck R; Seidl C; Pfost B; Morgenstern A; Bruchertseifer F; Baum H; Schwaiger M; Senekowitsch-Schmidtke R
Cancer Sci; 2007 Aug; 98(8):1215-22. PubMed ID: 17561973
[TBL] [Abstract][Full Text] [Related]
3. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Seidl C; Zöckler C; Beck R; Quintanilla-Martinez L; Bruchertseifer F; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):312-22. PubMed ID: 21072513
[TBL] [Abstract][Full Text] [Related]
4. 213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe.
Seidl C; Port M; Gilbertz KP; Morgenstern A; Bruchertseifer F; Schwaiger M; Röper B; Senekowitsch-Schmidtke R; Abend M
Mol Cancer Ther; 2007 Aug; 6(8):2346-59. PubMed ID: 17699730
[TBL] [Abstract][Full Text] [Related]
5. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM; Seidl C; Beck R; Saur D; Apostolidis C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):841-9. PubMed ID: 17206415
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells.
Seidl C; Port M; Apostolidis C; Bruchertseifer F; Schwaiger M; Senekowitsch-Schmidtke R; Abend M
Invest New Drugs; 2010 Feb; 28(1):49-60. PubMed ID: 19139817
[TBL] [Abstract][Full Text] [Related]
8. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.
Vandenbulcke K; De Vos F; Offner F; Philippé J; Apostolidis C; Molinet R; Nikula TK; Bacher K; de Gelder V; Vral A; Lahorte C; Thierens H; Dierckx RA; Slegers G
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1357-64. PubMed ID: 12845484
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.
Miederer M; Seidl C; Beyer GJ; Charlton DE; Vranjes-Duric S; Comor JJ; Huber R; Nikula T; Apostolidis C; Schuhmacher C; Becker KF; Senekowitsch-Schmidtke R
Radiat Res; 2003 May; 159(5):612-20. PubMed ID: 12710872
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.
Friesen C; Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E
Eur J Cancer; 2013 Jul; 49(11):2542-54. PubMed ID: 23684782
[TBL] [Abstract][Full Text] [Related]
12. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
Senekowitsch-Schmidtke R; Schuhmacher C; Becker KF; Nikula TK; Seidl C; Becker I; Miederer M; Apostolidis C; Adam C; Huber R; Kremmer E; Fischer K; Schwaiger M
Cancer Res; 2001 Apr; 61(7):2804-8. PubMed ID: 11306447
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate.
Li Y; Cozzi PJ; Qu CF; Zhang DY; Abbas Rizvi SM; Raja C; Allen BJ
Cancer Lett; 2004 Mar; 205(2):161-71. PubMed ID: 15036648
[TBL] [Abstract][Full Text] [Related]
15. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
[TBL] [Abstract][Full Text] [Related]
16. Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study.
Vandenbulcke K; Thierens H; Offner F; Janssens A; de Gelder V; Bacher K; Philippé J; De Vos F; Dierckx R; Apostolidis C; Morgenstern A; Slegers G
Nucl Med Commun; 2004 Nov; 25(11):1131-6. PubMed ID: 15577593
[TBL] [Abstract][Full Text] [Related]
17. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.
Li Y; Wang J; Rizvi SM; Jager MJ; Conway RM; Billson FA; Allen BJ; Madigan MC
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4365-71. PubMed ID: 16303921
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
[TBL] [Abstract][Full Text] [Related]
19. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation.
Wulbrand C; Seidl C; Gaertner FC; Bruchertseifer F; Morgenstern A; Essler M; Senekowitsch-Schmidtke R
PLoS One; 2013; 8(5):e64730. PubMed ID: 23724085
[TBL] [Abstract][Full Text] [Related]
20. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
